Telehealth Interventions for Supportive Management and Early Recognition of Treatment-Related Symptoms in Patients With Hematologic Malignancies.
Journal
Journal of the advanced practitioner in oncology
ISSN: 2150-0878
Titre abrégé: J Adv Pract Oncol
Pays: United States
ID NLM: 101550346
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
entrez:
17
3
2022
pubmed:
18
3
2022
medline:
18
3
2022
Statut:
ppublish
Résumé
The purposes of this literature review were to (1) establish the utility of supportive telehealth interventions focusing on early identification of treatment-related symptoms in adult patients with hematologic malignancies, with a secondary aim to (2) evaluate acceptability and feasibility. A literature review was conducted using PubMed, Cochrane Database of Systematic Reviews, CINAHL, Scopus, and Embase. Dates searched were from January 2007 through December 2019. Inclusion criteria included a diagnosis of hematologic malignancy, incorporation of telehealth interventions, effects on physiological outcomes, and participants ages 18 or older. Articles were excluded if they were a duplicate, had an irrelevant title, or were an incomplete study. Results indicated overall utility, acceptability, and feasibility of the interventions, including improved awareness of late and long-term therapy-related sequelae in survivorship, an overall decline in the number of chemotherapy delays with decreased rates in dose reductions, a means to further manage exercise remotely, and finally, improved communication between provider and patient with real-time management of acute and chronic treatment-related side effects using supportive telemetric interventions. Overall, the use of telehealth interventions in adult patients with hematologic malignancies positively impacts patient health, and telehealth interventions were found to be both accepted and feasible. Future studies should be directed at the role and involvement of the advanced practitioner, and current literature calls for well-planned studies as methodologic limitations remain in the evidence.
Identifiants
pubmed: 35295540
doi: 10.6004/jadpro.2021.12.8.5
pii: 2021.12.8.5
pmc: PMC8631342
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
835-849Informations de copyright
© 2021 Harborside™.
Déclaration de conflit d'intérêts
Authors’ disclosures of conflicts of interest are found at the end of this article.
Références
Ann Hematol. 2019 Apr;98(4):931-939
pubmed: 30778715
Bone Marrow Transplant. 2014 Jun;49(6):786-92
pubmed: 24710562
J Cancer Surviv. 2018 Jun;12(3):357-370
pubmed: 29411314
Support Care Cancer. 2020 Mar;28(3):1469-1479
pubmed: 31273501
JMIR Mhealth Uhealth. 2018 Mar 19;6(3):e66
pubmed: 29555620
JMIR Mhealth Uhealth. 2016 Sep 09;4(3):e107
pubmed: 27613084
Ann Hematol. 2008 Apr;87(4):277-83
pubmed: 17952688
JCO Clin Cancer Inform. 2018 Dec;2:1-10
pubmed: 30652594
Lancet Oncol. 2008 Feb;9(2):105-16
pubmed: 18226581
Am J Prev Med. 2013 Oct;45(4):517-23
pubmed: 24050429
Blood. 2020 Dec 17;136(25):2881-2892
pubmed: 33113551
Transplantation. 2007 Mar 15;83(5):554-60
pubmed: 17353773
Int J Nurs Stud. 2011 Aug;48(8):926-32
pubmed: 21349519
J Clin Exp Hematop. 2011;51(1):1-5
pubmed: 21628854